Anus Neoplasms
12
0
1
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
8.3%
1 terminated out of 12 trials
90.0%
+3.5% vs benchmark
8%
1 trials in Phase 3/4
44%
4 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (12)
Proton Therapy in Reducing Toxicity in Anal Cancer
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.
Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients
Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream
Tolerability, Safety, & Efficacy of Argon Plasma Coagulation to Treat Anal Intraepithelial Neoplasia in HIV-Positive Men
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection
The Feasibility of Self or Partner-assisted Digital Anal Exam Screening
Men's Beliefs About Associations Between HPV, Cancers, and HPV Vaccination
Alkagin Paste in the Prevention of Radiation Dermatitis
A Study of Anal Cancer Development in HIV Infected People